Compare Crispr Therapeutics AG (CRSP) vs Cintas Corporation (CTAS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Cintas Corporation — how do they compare? Crispr Therapeutics AG trades at $53.85 (market cap $5.23B), while Cintas Corporation trades at $205.78 (market cap $82.15B). The key difference: Cintas Corporation is far larger — about 15.7× Crispr Therapeutics AG's market cap, and Cintas Corporation pays a 1.01% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | CTAS | |
|---|---|---|
Market Cap | $5.23B | $82.15B |
Sector | Health | Industrials |
52-Week High | $76.78 | $225.10 |
52-Week Low | $44.34 | $163.55 |
Enterprise Value | $3.65B | $84.56B |
Dividend Yield | — | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
Cintas (CTAS) trades at $203.51, up 0.39% on the day, with a bullish technical signal and recent earnings beats driving momentum. The company reported strong fiscal 2026 results with revenue of $10.34 billion and net income of $1.81 billion, supported by robust profitability margins. Analyst consensus is a 'Buy' with a $225.83 price target, though valuation multiples like a P/E of 41.81 suggest premium pricing. Recent news highlights dividend declarations and institutional buying interest.
Outlook remains positive given consistent earnings outperformance and upward revenue guidance, but risks include high valuation sensitivity and economic cyclicality. The stock offers growth potential from operational efficiency and market share gains, yet investors should weigh elevated multiples against sector peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →
